Evidence map›Paper›PMID 41778789›Full record

ArticleJournal of virology2026

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.

Tugba Atabey, Ronald Derking, Maddy L Newby, Joey H Bouhuijs, Jonne L Snitselaar, Monique Vink, Yoann Aldon, Joel D Allen, Max Crispin, Rogier W Sanders

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Tugba AtabeyAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-0196-594X
Ronald DerkingAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-2712-4316
Maddy L NewbyBiological Sciences, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-0624-245X
Joey H BouhuijsAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-6074-8542
Jonne L SnitselaarAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-2425-8335
Monique VinkAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Yoann AldonAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0001-9831-9391
Joel D AllenBiological Sciences, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-2547-968X
Max CrispinBiological Sciences, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-1072-2694
Rogier W SandersAmsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-2324-8573

Funding

Structural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4M
Bill and Melinda Gates Foundation INV-063951Bill and Melinda Gates Foundation INV-070116Gates Foundation INV-002022NIH HHS P01 AI110657
6 · The paper itself

Abstract

N-linked glycosylation of glycoproteins during synthesis in the endoplasmic reticulum (ER) is mediated by oligosaccharyltransferase (OST) complexes OST-A and OST-B that have different catalytic subunits STT3A and STT3B, respectively. OST-A acts cotranslationally, while OST-B adds glycans posttranslationally. While there is redundancy between these two enzymes, it is unclear how they both contribute to glycosylation of the densely glycosylated HIV-1 envelope glycoprotein complex (Env). We found that knocking out STT3A had a profound negative impact on HIV-1 virus production and infectivity, while STT3B ablation had no such effect, suggesting that STT3A is more important than STT3B for Env glycosylation and preserved function. STT3A/3B knockout (KO) affected the neutralization sensitivity to broadly neutralizing antibodies (bNAbs) in a strain-specific manner, with STT3A-KO increasing susceptibility to VRC01 bNAb for the tested HIV-1 strains. In contrast, for the BG505 clade A virus, it conferred increased resistance to glycan-dependent bNAbs 2G12 and PGT128. For other HIV-1 strains, STT3B-KO also led to resistance to glycan-dependent bNAb PGT151. Site-specific glycan analysis of recombinant Env proteins revealed that STT3A-KO reduced glycan occupancy of potential N-linked glycosylation sites (PNGS) more globally than STT3B-KO, with certain acceptor sites, including N234 and N386, showing STT3A dependence. In contrast, STT3B-KO appeared to have a more pronounced effect on gp41 glycosylation, suggesting that PNGS located near the C-terminus are more dependent on STT3B. Defining the roles of the OST-A and OST-B complexes in HIV-1 Env glycosylation may bring critical information for the development of methods to control PNGS glycan occupancy of recombinant glycoprotein immunogens.IMPORTANCEHIV-1 envelope glycoprotein (Env) complex is the sole target of broadly neutralizing antibodies (bNAbs), making it the primary focus of vaccine design efforts. The Env glycoprotein is one of the most heavily glycosylated proteins found in nature. However, the contributions of oligosaccharyltransferase (OST) isoforms STT3A and STT3B to Env glycosylation have not been fully characterized. Under-occupancy of potential N-linked glycosylation sites (PNGS) on recombinant Env glycoproteins can elicit off-target immune responses and pose challenges for HIV-1 vaccine development. Understanding and controlling the mechanisms behind PNGS occupancy is therefore critical for rational immunogen design. This study demonstrated that the viral Env glycosylation is mostly controlled by OST-A. Additionally, site-specific glycan analysis of recombinant Env proteins identified several STT3A-dependent sites and confirmed a dominant role of STT3B in C-terminal glycosylation. Our fundamental study contributes novel insights into host-cell-mediated glycosylation and informs the development of methods to regulate PNGS occupancy of Env-based immunogens.

Indexed as

env Gene Products, Human Immunodeficiency VirusHexosyltransferasesHIV-1Membrane ProteinsAntibodies, NeutralizingGene Knockout TechniquesGlycosylationHumansAntibodies, Neutralizingdolichyl-diphosphooligosaccharide - protein glycotransferaseenv Gene Products, Human Immunodeficiency VirusHexosyltransferasesMembrane ProteinsSTT3A protein, humanSTT3B protein, humanenvelope glycoproteinHIVN-linked glycosylationoligosaccharyltransferaseSTT3ASTT3B

Identifiers

PMID41778789
PMCPMC13011424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.